{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:59:15Z","timestamp":1772690355687,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1993,2,1]],"date-time":"1993-02-01T00:00:00Z","timestamp":728524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1993,2,1]],"date-time":"1993-02-01T00:00:00Z","timestamp":728524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1993,2]]},"DOI":"10.1007\/bf00873916","type":"journal-article","created":{"date-parts":[[2004,12,24]],"date-time":"2004-12-24T19:39:55Z","timestamp":1103917195000},"page":"75-79","source":"Crossref","is-referenced-by-count":16,"title":["Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer"],"prefix":"10.1007","volume":"11","author":[{"given":"G. T.","family":"Budd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. M.","family":"Bukowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lichtin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Van Kirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ganapathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00873916_CR1","first-page":"938","volume":"28","author":"D Kessel","year":"1968","unstructured":"Kessel D, Botteril V, Wodinski I: Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Research 28:938\u2013941, 1968","journal-title":"Cancer Research"},{"key":"BF00873916_CR2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.3457471","volume":"232","author":"DW Shen","year":"1986","unstructured":"Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, Gottesman MM: Human multidrug-resistant cell lines: increased mdrl expression can precede gene amplification. Science 232:643\u2013645, 1986","journal-title":"Science"},{"key":"BF00873916_CR3","first-page":"4039","volume":"6","author":"DW Shen","year":"1986","unstructured":"Shen DW, Fojo A, Roninson IB, Chen JE, Soffir R, Pastan I, Gottesman MM: Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdrl gene. Molecular and Cellular Biology 6:4039\u20134045, 1986","journal-title":"Molecular and Cellular Biology"},{"key":"BF00873916_CR4","first-page":"3075","volume":"46","author":"Y Pommier","year":"1986","unstructured":"Pommier Y, Kerrigan D, Schwartz RE, Swack JA, McCurdy A: Altered DNA topoisomerase II activity in Chinese Hamster cells resistant to topoisomerase II inhibitors. Cancer Research 46:3075\u20133081, 1986","journal-title":"Cancer Research"},{"key":"BF00873916_CR5","first-page":"1967","volume":"41","author":"T Tsuruo","year":"1981","unstructured":"Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced by cytotoxicity of vincristine and vinblastine by verapamil. Cancer Research 41:1967\u20131972, 1981","journal-title":"Cancer Research"},{"key":"BF00873916_CR6","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/0006-2952(81)90246-X","volume":"30","author":"M Inaba","year":"1981","unstructured":"Inaba M, Fujikura R, Tsukagoshi S, Sakurai Y: Restored in vitro sensitivity of adriamycin- and vincristine-resistant P388 leukemia with reserpine. Biochemical Pharmacology 30:2191\u20132194, 1981","journal-title":"Biochemical Pharmacology"},{"key":"BF00873916_CR7","first-page":"3696","volume":"43","author":"R Ganapathi","year":"1983","unstructured":"Ganapathi R, Grabowski D: Enhancement of sensitivity to Adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Research 43:3696\u20133699, 1983","journal-title":"Cancer Research"},{"key":"BF00873916_CR8","first-page":"4730","volume":"42","author":"T Tsuruo","year":"1982","unstructured":"Tsuruo T, Iida H, Tsukagoski S, Sakurai Y: Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Research 42:4730\u20134733, 1982","journal-title":"Cancer Research"},{"key":"BF00873916_CR9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1200\/JCO.1987.5.4.641","volume":"5","author":"RF Ozols","year":"1987","unstructured":"Ozols RF, Cunnionb RE, Klecker RW, Hamilton TC, Ostechaga Y, Parrillo JE, Young RC: Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients. Journal of Clinical Oncology 5:641\u2013647, 1987","journal-title":"Journal of Clinical Oncology"},{"key":"BF00873916_CR10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.1989.7.4.415","volume":"7","author":"WS Dalton","year":"1989","unstructured":"Dalton WS, Grogan TM, Moltzer PS, Scheper RJ, Durie BCM, Taylor CW, Miller TP, Salmon SE: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. Journal of Clinical Oncology 7:415\u2013424, 1989","journal-title":"Journal of Clinical Oncology"},{"key":"BF00873916_CR11","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1200\/JCO.1988.6.5.880","volume":"6","author":"RL Miller","year":"1988","unstructured":"Miller RL, Bukowski RM, Budd GT, Purvis J, Weick JK, Shepard K, Midha KK, Ganapathi R: Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a Phase I\/II trial. Journal of Clinical Oncology 6:880\u2013888, 1988","journal-title":"Journal of Clinical Oncology"},{"key":"BF00873916_CR12","first-page":"1181","volume":"70","author":"M Andersson","year":"1986","unstructured":"Andersson M, Daugaard S, von der Maase, Mouridsen HT: Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study. Cancer Treatment Reports 70:1181\u20131186, 1986","journal-title":"Cancer Treatment Reports"},{"key":"BF00873916_CR13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.1986.4.5.672","volume":"4","author":"JA Neidhart","year":"1986","unstructured":"Neidhart JA, Gochnour D, Roach R, Hoth D, Young D: A comparison of mitoxantrone and doxorubicin in breast cancer. Journal of Clinical Oncology 4:672\u2013677, 1986","journal-title":"Journal of Clinical Oncology"},{"key":"BF00873916_CR14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/JCO.1989.7.5.560","volume":"7","author":"IC Henderson","year":"1989","unstructured":"Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. Journal of Clinical Oncology 7:560\u2013571, 1989","journal-title":"Journal of Clinical Oncology"},{"key":"BF00873916_CR15","first-page":"1077","volume":"83","author":"JD Cowan","year":"1991","unstructured":"Cowan JD, Neidhart J, McClure S, Coltman CA, Gumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK: Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. Journal of Clinical Oncology 83:1077\u20131084, 1991","journal-title":"Journal of Clinical Oncology"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873916.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00873916\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873916.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T03:41:49Z","timestamp":1678506109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00873916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,2]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1993,2]]}},"alternative-id":["BF00873916"],"URL":"https:\/\/doi.org\/10.1007\/bf00873916","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,2]]}}}